Xingjuan Chao Sells 5,700 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 5,700 shares of CeriBell stock in a transaction that occurred on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total value of $85,614.00. Following the transaction, the chief executive officer now owns 746,451 shares of the company's stock, valued at $11,211,694.02. This represents a 0.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, April 23rd, Xingjuan Chao sold 15,628 shares of CeriBell stock. The stock was sold at an average price of $15.11, for a total value of $236,139.08.
• On Monday, April 21st, Xingjuan Chao sold 3,372 shares of CeriBell stock. The shares were sold at an average price of $15.03, for a total transaction of $50,681.16.

CeriBell Stock Down 1.2 %

NASDAQ:CBLL traded down $0.18 during trading hours on Friday, reaching $15.31. 246,142 shares of the company were exchanged, compared to its average volume of 272,868. CeriBell has a 52-week low of $10.01 and a 52-week high of $32.75. The company's 50 day moving average is $19.64.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analysts' expectations of $17.55 million. Research analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.

Institutional Trading of CeriBell

Institutional investors have recently modified their holdings of the company. Legal & General Group Plc acquired a new position in CeriBell during the fourth quarter valued at approximately $32,000. Summit Investment Advisors Inc. purchased a new stake in CeriBell during the 4th quarter worth $33,000. Tower Research Capital LLC TRC acquired a new stake in CeriBell in the 4th quarter valued at $37,000. BNP Paribas Financial Markets purchased a new position in CeriBell in the fourth quarter valued at about $43,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of CeriBell during the fourth quarter worth about $47,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $32.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.